Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Exam Prep1
- Article Type
- Clinical Trial1
- Clinical Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Clin Pharmacol Ther1
Search Results
Sort by
- BookTheresa Clifford, Denise O'Brien.Contents:
Certification of perianesthesia nurses : CPAN and CAPA certification programs
Respiratory, cardiovascular, peripheral vascular and hematologic systems
Neurologic and gastrointestinal systems
Renal and integumentary systems
Genitourologic, reproductive, and musculoskeletal systems
Endocrine system, fluids, and electrolytes
Maintenance of normothermia, physiologic comfort, and the therapeutic environment
Anesthesia and malignant hyperthermia
Diversity and psychosocial assistance
Patient and family education
ASPAN standards, documentation, regulatory guidelines, and patient safety needs.Digital Access R2Library 2018Limited to 2 simultaneous users - ArticleCaterson RJ, Collett PV, Hood VL, Duggin GG, Horvath JS, Johnson JR, Sampson J, Tiller DJ.Clin Pharmacol Ther. 1978 May;23(5):553-7.Twenty-two patients with functioning renal allografts took part in a double-blind crossover trial during which placebo, sulfamethoxazole, and trimethoprim/sulfamethoxazole were given for periods of 14 days. The patients were divided into 2 groups. The first group consisting of 12 patients had serum creatinine levels less than 0.18 mmol/L and the second group of 10 patients had serum creatinine levels between 0.18 mmol/L and 0.35 mmol/L. Renal function at the end of each period was assessed by clearance of inulin (CIn), p-aminohippurate (CPAH) and endogenous creatinine (CCr). The second group also had a pitressin concentration test as a measure of distal tubule function. There was no change in inulin or creatinine clearance or in maximum concentration after pitressin in any of the patients in any of the phases. In the first group there was an increase in PAH clearance during the sulfonamide and trimethroprim/sulfamethoxazole phases. This change was not seen in the second group of patients with significantly impaired renal function.